Drugs that contain Umeclidinium Bromide; Vilanterol Trifenatate

1. Drug name - ANORO ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44874 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(5 months from now)

US7498440 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(2 years from now)

US7439393 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(2 years from now)

US7488827 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Dec, 2027

(5 years from now)

CN1976701A GLAXOSMITHKLINE Machrs Antagonist
May, 2012

(10 years ago)

CN103288793A GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(18 days ago)

CN1585633A GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(18 days ago)

CN101701006A GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(18 days ago)

CN103288793B GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(18 days ago)

CN101701006B GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(18 days ago)

CN1585633B GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2022

(18 days ago)

IN212714B GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases.
Sep, 2022

(18 days ago)

IN200400346P2 GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases.
Sep, 2022

(18 days ago)

IN255064B GLAXOSMITHKLINE 4-[Hydroxy(Diphenyl)Methyl]-1-(2-[(Phenylmethyl)Oxy]Ethyl}-1-Azoniabicyclo[2.2.2.]Octane Bromide
Apr, 2025

(2 years from now)

IN200605413P1 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP2042168A1 GLAXOSMITHKLINE Inhalation Formulation Comprising Phenethanolamine Derivatives For The Treatment Of Respiratory Diseases
Sep, 2022

(18 days ago)

EP2042168B1 GLAXOSMITHKLINE Inhalation Formulation Comprising Phenethanolamine Derivatives For The Treatment Of Respiratory Diseases
Sep, 2022

(18 days ago)

EP2570128A1 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP2570128B1 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177A4 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177B1 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177A2 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1425001A1 GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2027

(4 years from now)

EP1425001B1 GLAXOSMITHKLINE Phenethanolamine Derivatives For Treatment Of Respiratory Diseases
Sep, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309572 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists Apr, 2025

(2 years from now)

US8183257 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists Jul, 2025

(2 years from now)

US8511304 GLAXOSMITHKLINE Medicament dispenser Jun, 2027

(4 years from now)

US9333310 GLAXOSMITHKLINE Medicament dispenser Oct, 2027

(5 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser Oct, 2027

(5 years from now)

US8161968 GLAXOSMITHKLINE Medicament dispenser Feb, 2028

(5 years from now)

US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser Mar, 2030

(7 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser Oct, 2030

(8 years from now)

US11090294 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist Nov, 2030

(8 years from now)

US9750726 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist Nov, 2030

(8 years from now)

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.; Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription

availability in other generic markets.

Click on the highlighted region to filter.